D75.84
Other platelet-activating anti-PF4 disorders
Clinical Classification Guidelines
Use Additional Code
- code, if applicable, for adverse effect of other viral vaccine (T50.B95-)
Inclusion Terms
- Spontaneous heparin-induced thrombocytopenia syndrome (without heparin exposure)
- Thrombosis with thrombocytopenia syndrome
- Vaccine-induced thrombotic thrombocytopenia
Medical Intelligence & Overview
Other platelet-activating anti-PF4 disorders encompass a group of rare immune-mediated conditions characterized by the activation of platelets due to antibodies directed against platelet factor 4 (PF4). These disorders often lead to either an increased risk of blood clots or a decrease in platelet counts, which can result in bleeding complications. Notable conditions within this category include spontaneous heparin-induced thrombocytopenia syndrome (without prior heparin exposure), thrombosis with thrombocytopenia syndrome (TTS), and vaccine-induced thrombotic thrombocytopenia (VITT). Recognizing these conditions is crucial due to their potential severity and the need for timely management.
Causes & Symptoms
Clinical Causes: Development of antibodies against PF4 that activate platelets Spontaneous formation of anti-PF4 antibodies without prior heparin exposure Following certain vaccinations, notably COVID-19 vaccines, which can trigger VITT Potential genetic predispositions or immune system irregularities Unknown triggers in some cases leading to thrombosis and thrombocytopenia
Key Symptoms: Unexplained blood clots in veins or arteries Thrombocytopenia, resulting in easy bruising or bleeding Severe headache or neurological symptoms if cerebral veins are affected Swelling, redness, or pain in affected limbs Shortness of breath or chest pain if pulmonary embolism occurs Fever and malaise in some cases
Diagnostic & Treatment
Diagnosis Path: Blood tests revealing low platelet counts Imaging studies such as ultrasound or CT scans to detect blood clots Serological assays to identify anti-PF4 antibodies, including ELISA tests Exclusion of other causes of thrombocytopenia or thrombosis Assessment of timing related to recent vaccinations or heparin exposure
Treatment Protocols: Use of non-heparin anticoagulants (e.g., danaparoid, fondaparinux, direct oral anticoagulants) Avoidance of platelet transfusions unless bleeding is significant Administration of intravenous immunoglobulin (IVIG) to neutralize pathogenic antibodies Monitoring platelet counts and signs of new or progressing clots Supportive care tailored to individual patient needs In cases related to vaccination, prompt recognition and treatment are vital
Clinical Advice & FAQs
Billing Guidance
Is D75.84 a billable ICD-10 code?
Yes, D75.84 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D75.84?
Clinical documentation must specify the nature of Other platelet-activating anti-PF4 disorders and any associated comorbidities for accurate reporting.
Cite this Clinical Reference